Promising melanoma drug that shrinks brain tumor: Australian researchers say
Linkedin

Promising melanoma drug that shrinks brain tumor: Australian researchers say

Sydney : Australia | May 20, 2012 at 7:02 AM PDT
XX XX
Views: Pending
 
New hope for melanoma patients

A new melanoma drug developed by Australian researchers offers a ray of hope for those suffering from brain metastases commonly known as brain tumor. As per data collected from an phase I/II study and published in The Lancet; a British medical journal on Friday (May 18th), the new drug shows great promise in shrinking brain tumors in melanoma patients.

The researchers’ teams from the Melanoma Institute Australia (MIA) and Sydney’s Westmead Hospital have developed the experimental drug, which is able to add crucial months to the lives of patients with brain melanoma. It may be noted that in advanced melanoma cancer, the tumor has already spread to the brain. When that happens, a patient does not survive beyond four months.

The results of the trial by Australian researchers showed significant shrinking of brain tumors in cancer stricken patients treated with the drug, Dabrafenib. It also showed promise against secondary melanoma tumors, or metastases, in the brain. This experimental drug was able to increase the patients’ life span up-to five months and in some cases they were able to survive even beyond 19 months. Basically the drug, Dabrafenib blocks the activity of the cancer-causing mutated gene called BRAF, which is found in about half of melanoma cases.

Speaking about the trial, lead researcher Georgina Long, a medical oncologist, said that the researchers recruited 184 patients who were suffering from varied forms of melanoma cancer. Among them were ten patients suffering from brain tumors, which is known as metastases.

The outcome of the trial using drug Dabrafenib, was remarkable. In five patients the brain metastases had shrunk, and one had stable disease, whereas the tumors remained the same size. "The results across all the patients in the study were phenomenal . . . until now there has not been a single drug that has shrunk brain metastases", declared an elated Long.

Even experts not involved in the trial opine the drug is impressive and showed promise. The research result is a great step forward for brain cancer research and offers hope of survival for patients, suffering from brain metastases, in the future.

Source: Chicago Tribune/Top News.

Other health related news:

Salmonella outbreak across 18 states in US: 300 fall sick

9-year-old to McDonald's CEO: Stop ‘tricking kids’ into eating junk food

Eat insects to combat world hunger, UN agency says

Three cups of tea a day, tonic for high blood pressure: say researchers

New bird flu strain found in China 'one of the most lethal' viruses: WHO

Genistein - soya bean hormone key to wrinkle-free skin, say scientists

World’s first woman to have womb transplant, is pregnant: hospital

US soldier Brendan Marrocco after double-arm transplant says ‘It feels amazing’

£30 anti-wrinkle cream that will stop women going under knife

A virus that eats away cancer but cure languishing in freezer

Promising single jab of ‘DNA vaccine’ to help quit smoking (Video)

1 of 4
Next
Australian doctors say a new drug is showing excellent signs of fighting melanoma, even after the deadly disease has spread.
Nina Rai is based in Mangaluru, Karnataka, India, and is an Anchor for Allvoices.
Report Credibility
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
 
 
Advertisement
 

News Stories

 

Blogs

 >
  • New melanoma drug may shrink brain tumors

    Submitted By: NinaRai | 27 days ago
    Home News New melanoma drug may shrink brain tumors An experimental melanoma drug from GlaxoSmithKline managed to shrink secondary tumors in the brains of nine patients with advanced disease, according to results of a small clinical trial on Sunday.

Images

 >
 

More From Allvoices

Report Your News Got a similar story?
Add it to the network!

Or add related content to this report



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.